AZD2461: Novel PARP Inhibitor for Breast Cancer Research

Executive Summary: AZD2461 is a potent PARP inhibitor with an IC₅₀ of 5 nM, demonstrating strong cytotoxicity against human breast cancer cell lines MCF-7 and SKBR-3 in a concentration- and time-dependent manner (Schwartz 2022). The compound induces cell cycle arrest at the G2 phase and reduces S-phase populations in vitro. In vivo, AZD2461 maintains PARP inhibition in murine KB1P tumor models for several hours, with PAR levels returning to baseline by 24 hours post-administration. AZD2461 shows lower affinity for P-glycoprotein (Pgp) than olaparib, potentially overcoming Pgp-mediated resistance. Long-term administration in mice is well tolerated and significantly extends relapse-free survival compared to controls (UMassChan eScholarship).

Biological Rationale

Poly (ADP-ribose) polymerase (PARP) enzymes facilitate DNA repair by catalyzing the transfer of ADP-ribose units to target proteins, essential for maintaining genomic integrity. Inhibition of PARP, particularly PARP-1, impairs DNA repair, leading to synthetic lethality in cancer cells with homologous recombination deficiencies, such as those with BRCA1 mutations (Schwartz 2022). The therapeutic rationale for PARP inhibitors in oncology is grounded in exploiting such vulnerabilities in tumor cells while sparing normal cells with intact DNA repair pathways. AZD2461, supplied by APExBIO, is engineered to enhance efficacy in breast cancer models by targeting these DNA repair mechanisms (product page).

Mechanism of Action of AZD2461

AZD2461 selectively inhibits PARP-1 enzyme activity with an in vitro IC₅₀ value of 5 nM, resulting in impaired base excision repair and accumulation of DNA strand breaks. This leads to activation of cell cycle checkpoints and G2-phase arrest, as evidenced by increased G2 population and decreased S-phase cells in MCF-7 and SKBR-3 breast cancer cell lines following treatment at 5–50 μM for 48–72 hours (Schwartz 2022). In vivo, AZD2461 administration in mice bearing KB1P tumors leads to acute PARP inhibition, with restoration of baseline PAR levels within 24 hours, indicating a reversible pharmacodynamic profile (UMassChan eScholarship). Unlike olaparib, AZD2461 demonstrates lower affinity for P-glycoprotein, reducing the risk of multidrug resistance associated with Pgp-mediated efflux (related article).

Evidence & Benchmarks

• AZD2461 inhibits PARP-1 activity in vitro with an IC₅₀ of 5 nM (Schwartz 2022, DOI).
• Reduces cell viability in MCF-7 and SKBR-3 breast cancer cell lines in a concentration- and time-dependent manner (48–72 h, 5–50 μM) (Schwartz 2022).
• Induces cell cycle arrest, increasing the G2-phase population and decreasing S-phase cells in treated breast cancer cultures (Schwartz 2022, DOI).
• In murine KB1P tumor models, AZD2461 maintains PARP inhibition for several hours post-dose; PAR levels return to baseline after 24 hours (UMassChan eScholarship).
• Exhibits lower affinity for P-glycoprotein compared to olaparib, suggesting enhanced efficacy in Pgp-expressing, drug-resistant cells (related article).
• Long-term administration is well tolerated and significantly extends median relapse-free survival in tumor-bearing mice (Schwartz 2022, DOI).

This article builds on "AZD2461: Novel PARP Inhibitor Transforming Breast Cancer ..." by providing updated dosing guidelines and comparative Pgp-affinity data, clarifying the molecular advantages of AZD2461 for translational workflows.

For a more in-depth mechanistic perspective, see "AZD2461 and the Next Evolution of PARP Inhibition: Mechan...", which this article extends by detailing practical integration and experimental controls specific to breast cancer cell lines.

Applications, Limits & Misconceptions

AZD2461 is primarily used for in vitro and in vivo studies probing the DNA repair pathway, synthetic lethality, and drug resistance in breast cancer and BRCA1-mutated models. It is especially valued in settings where overcoming Pgp-mediated resistance is critical (related article). Its reversible pharmacodynamics make it suitable for studies requiring temporal control over PARP inhibition.

Common Pitfalls or Misconceptions

• AZD2461 is not water-soluble; improper dissolution can result in poor bioavailability in cell culture experiments.
• It is not suitable as a substitute for cytotoxic chemotherapeutics; its efficacy is specific to tumors with defective homologous recombination repair.
• Pgp-mediated resistance is reduced but not eliminated; high Pgp expression may still confer partial resistance.
• Long-term storage of AZD2461 solutions at room temperature leads to degradation; solutions should be prepared fresh or stored at -20°C for short-term use.
• Not all breast cancer cell lines are sensitive; selection should be guided by molecular profiling (e.g., BRCA1 status).

Workflow Integration & Parameters

For cell-based assays, dissolve AZD2461 in DMSO (minimum solubility 16.35 mg/mL) or ethanol (≥45.2 mg/mL with ultrasonic assistance). Working concentrations range from 5 to 50 μM, with typical incubation periods of 48–72 hours. For in vivo studies, dosing must ensure PARP inhibition while limiting toxicity; refer to published murine protocols for guidance (UMassChan eScholarship). Always store the solid compound at -20°C and minimize freeze-thaw cycles. The AZD2461 A4164 kit from APExBIO includes validated handling instructions.

Conclusion & Outlook

AZD2461 is a robust, next-generation PARP inhibitor for breast cancer and DNA repair research. Its high potency, reduced Pgp affinity, and favorable in vivo tolerability set it apart from earlier inhibitors. Continued adoption of AZD2461 is expected to enhance studies on synthetic lethality and drug resistance, particularly in BRCA1-mutated and relapse-prone tumor models. For validated protocols and ordering information, refer to the official APExBIO product page. For expanded context on translational parameters, see this recent update, which this article updates with the latest evidence and workflow guidance.